Question: Should I give this patient pharmacotherapy? Comment: The decision to begin antihypertensive drug therapy must take into account the patient's future cardiovascular risk. "White coat" (or office-induced) hypertension may also need to be excluded before drug therapy is started. Given this patient's blood pressure and cardiovascular risk factors (age and dyslipidemia), she would benefit from an antihypertensive agent. The results of numerous clinical studies have demonstrated that with moderately elevated blood pressure (≥ 160 mm Hg systolic or ≥ 100 mm Hg diastolic), antihypertensive therapy leads to 20%-25% reductions in cardiovascular morbidity and 5%-15% reductions in mortality. 1 When blood pressure is mildly increased (140-159 mm Hg systolic or 90-99 mm Hg diastolic), patients with macrovascular target organ damage or a number of cardiovascular risk factors would have sufficiently increased risk to warrant initiating drug therapy. Although β-blockers are a reasonable option for first-line therapy in younger patients and those with existing cardiovascular disease, they are not recommended as first-line monotherapy in patients 60 years of age or more. In a meta-analysis of patients 60 years and older, β-blocker monotherapy was no more effective than placebo in reducing the risk of coronary artery disease, cardiovascularrelated death or death due to any cause. 2 In the ALLHAT study, α-blockers were associated with a higher incidence of heart failure than were thiazide diuretics.
Question
3 Thus, α-blockers are not considered first-line agents for managing hypertension.
Question: I've decided to start this patient with hydrochlorothiazide at 12.5 mg per day. How should I monitor her for adverse effects? Comment: Metabolic disturbances such as hypokalemia, dyslipidemia and hyperglycemia occur infrequently with low doses of thiazide diuretic. Despite the occurrence of these abnormalities, the overall cardiovascular benefits remain. Evidence is lacking on the optimal frequency and timing of monitoring for adverse effects associated with antihypertensive agents. In our opinion, all patients starting on thiazide diuretics (even at low doses) should be screened after 4-6 weeks for glucose, electrolyte, creatinine and serum total cholesterol levels in case metabolic disturbances occur. Any abnormalities should prompt closer follow-up and correction. The risk of hypokalemia can be minimized among patients receiving thiazide diuretic monotherapy through the use of potassium-sparing agents (e.g., triamterene, aldactone, amiloride). For those taking ACE inhibitors or angiotensin-receptor blockers, serum creatinine levels should be monitored 2-4 weeks after therapy starts. Serum potassium and creatinine levels should be monitored at least 1-2 times per year thereafter. In general, if there are adverse effects with a single agent, another drug from any of the other appropriate first-line agents should be substituted.
Patients given drug therapy should return for follow-up blood pressure monitoring every 1-2 months until their target level is reached. Patients with severe hypertension, intolerance to antihypertensive drugs or target organ damage may need to be monitored more frequently. Once the target level is reached, blood pressure should be monitored at intervals of 3-6 months.
Question:
After increasing hydrochlorothiazide to a standard dose (25 mg per day), the patient's blood pressure is 162/92 mm Hg. Since this level is still above the target (< 140/90 mm Hg), what medication should be added? Comment: For most patients, reaching a target of less than 140/90 mm Hg requires 2 or more antihypertensive agents at standard doses. In a metaanalysis of 50 placebo-controlled trials evaluating drugs from 2 different classes separately and in combination, reductions in blood pressure with combination drug therapy were additive, and adverse effects were reported less often than expected. 4 Thus, if the blood pressure target has not been reached at the standard dose (rather than the maximum dose) of an antihypertensive agent, a second antihypertensive agent should be started and the dosage increased to the standard amount until the blood pressure target is met. Currently, there is little prospective evidence supporting starting with a combination of 2 drugs, although trials are ongoing.
For this patient, and in general, thiazide diuretics can be combined with any of the other major drug classes (calciumchannel blockers, β-blockers, ACE inhibitors or angiotensinreceptor blockers). On the basis of their complementary physiologic effects, other useful combinations include a calciumchannel blocker with either an 4 Using 3 agents, one would expect an even greater reduction in blood pressure, which is not apparent in our patient. When the patient is not responding to therapy and suboptimal treatment has been excluded, one must consider nonadherence, possible medication adverse effects, or resistant hypertension (Box 1).
Alternatively, if the patient describes symptoms of hypotension or reports lower blood pressure readings outside of the office setting, consider officeinduced hypertension. A 24-hour ambulatory blood pressure measuring device can be used to confirm this diagnosis. If the target blood pressure remains difficult to achieve, referral to a hypertension specialist should be considered.
On further discussion with this patient, she had stopped taking the enalapril because of a dry cough. We recommended that the enalapril be replaced with atenolol 50 mg daily. At the next follow-up visit, her blood pressure was 138/85 mm Hg, the target level.
Question: Many patients complain about "having to take so many pills." What strategies can help to improve adherence to the therapeutic regimen? Comment: Nonadherence to the therapeutic regimen may occur for a variety of reasons. Several strategies that can help to improve adherence are shown in Box 2.
